Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27688244 | 0.88 | TDP1 (0.40) | SIRT3TDP1NNMTMKNK1MKNK2 | |
| SCHEMBL27726519 | 0.88 | HAAO (0.40) | SIRT3TDP1POLBALDH1A1HPGD | |
| SCHEMBL1334612 | 0.84 | POLB (0.42) | SIRT3TDP1POLBALDH1A1HPGD | |
| SCHEMBL3357139 | 0.83 | SIRT3 (0.42) | SIRT3TDP1NNMTPOLBMKNK1 | |
| SCHEMBL354227 | 0.82 | SIRT3 (0.45) | SIRT3TDP1NNMTMKNK1MKNK2 | |
| SCHEMBL29889389 | 0.81 | NNMT (0.47) | SIRT3TDP1NNMTMKNK1MKNK2 | |
| SCHEMBL31307651 | 0.81 | POLB (0.48) | SIRT3TDP1POLBALDH1A1HPGD | |
| SCHEMBL1018603 | 0.81 | NNMT (0.47) | SIRT3TDP1NNMTMKNK1MKNK2 | |
| SCHEMBL1956878 | 0.81 | KDM4E (0.43) | SIRT3TDP1NNMTPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL1776795 | 0.80 | SIRT3 (0.44) | SIRT3TDP1NNMTMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120039815-A9 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-02-16 | — | — | US | claimed |
| US-20110256068-A1 | CONTRAST MEDIA COMPOSITIONS | GE HEALTHCARE AS (NO) | 2011-10-20 | — | — | US | claimed |
| US-20110052504-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-03-03 | — | — | US | claimed |
| CN-101983010-A | Dual pharmacophores-pde4-muscarinic antagonistics | GLAXO GROUP LTD | 2011-03-02 | — | — | CN | claimed |
| US-20110008263-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-13 | — | — | US | claimed |
| US-20100222581-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-02 | — | — | US | claimed |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | claimed |
| CN-101128439-A | 1,6 - substituted (3r,6r) -3- (2,3-dihydro-1h-inden-2-yl)-2,5-piperazinedione derivatives as oxytocin receptor antagonists for the treatment of pre-term labour, dysmenorrhea and endometriosis | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | CN | claimed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | claimed |
| EP-1537072-A1 | SUBSTITUTED AMINOETHERS FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia & Upjohn Company LLC (US) | 2005-06-08 | — | — | EP | claimed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
| WO-2004024675-A1 | SUBSTITUTED AMINOETHERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-25 | — | — | WO | claimed |
| WO-2004022523-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| JP-2004502669-A | — | — | 2004-01-29 | — | — | JP | claimed |
| EP-1353898-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| EP-1186305-A1 | New brominated compounds as contrast media for X-ray mammography | Schering Aktiengesellschaft (DE) | 2002-03-13 | — | — | EP | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| US-5204005-A | Decolorization, separation, purification of water-soluble nonionic contrast media compounds; removing nonionic impurities | MALLINCKRODT, INC. (US) | 1993-04-20 | — | — | US | claimed |
| WO-1991012868-A1 | REVERSED PHASE CHROMATOGRAPHIC PROCESS | MALLINCKRODT, INC. (US) | 1991-09-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039815-A9 | CONTRAST AGENTS | C5, TXN, CBR3 | SIRT3 1831/4885TDP1 4659/4885NNMT 2872/4885 |
| US-20110052504-A1 | CONTRAST AGENTS | C5, TXN, CBR3 | SIRT3 1831/4885TDP1 4659/4885NNMT 2872/4885 |
| US-20110008263-A1 | CONTRAST AGENTS | C5, C1R, C3AR1 | SIRT3 2443/4885TDP1 4530/4885NNMT 3960/4885 |
| US-20110256068-A1 | CONTRAST MEDIA COMPOSITIONS | FPR1, FPR3, TPO | SIRT3 2621/4885TDP1 3666/4885NNMT 2111/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | SIRT3 1082/4885TDP1 20/4885NNMT 220/4885 |
| US-20100222581-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BACE1, APP, BACE2 | SIRT3 2328/4885TDP1 636/4885NNMT 2079/4885 |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | BACE1, APP, BACE2 | SIRT3 3864/4885TDP1 332/4885NNMT 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.